Add Idarucizumab To Your DOAC Reversal Protocol for Dabigatran
December 2015
Idarucizumab eye-DAIR-yoo-siz-ooh-mab, Praxbind) will be the first reversal agent for ONE of the direct oral anticoagulants (DOACs).
It's an IV monoclonal antibody fragment that binds to the thrombin inhibitor, dabigatran (Pradaxa), to reverse anticoagulation.
But idarucizumab won't work for factor Xa inhibitors...rivaroxaban (Xarelto), apixaban (Eliquis), or edoxaban (Savaysa)...or other direct thrombin inhibitors like argatroban.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote